Skip to content

Success Rate of 4 Injection Protocols for Mandibular First Molars With Symptomatic Irreversible Pulpitis

Success Rate of 4 Injection Protocols for Mandibular First Molars With Symptomatic Irreversible Pulpitis: A CONSORT Randomized Triple-blind Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04929522
Enrollment
160
Registered
2021-06-18
Start date
2021-01-01
Completion date
2021-05-30
Last updated
2021-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Root Canal Infection

Keywords

intra-osseous injection, PDL injection, IANB

Brief summary

Achieving profound anesthesia during endodontic treatment of mandibular molars with symptomatic irreversible pulpitis is still a demanding clinical challenge. therefore, the success Rate of 4 Injection protocols for Mandibular First Molars with Symptomatic Irreversible Pulpitis was evaluated clinically in a randomized triple-blind trial

Detailed description

Trial design This study was a prospective, randomized, parallel, triple blinded, clinical trial. The present trial design methodology conforms to the CONSORT guidelines for reporting randomized clinical trials.Participants A sample size calculation was performed based on the study by (Kanaa M, Whitworth JM, Meechan JG. A Prospective Randomized Trial of Different Supplementary Local Anesthetic Techniques after Failure of Inferior Alveolar Nerve Block in Patients with Irreversible Pulpitis in Mandibular Teeth. J Endod 2012;38:421-425). This research was based on a type I error of 0.05 and a power of 0.8 and indicated that ideally a sample size of 36 in each group would be required to detect a 20% difference in the success rate of the test groups. To increase the validity of the study, 40 subjects in each group were considered.Ethical considerations This trial was conducted with the approval of the institutional review of board (IRB) of the ethics committee at the Faculty of Dentistry, Ain Shams University, Cairo, Egypt (FDASU-REC 772019). Patients signed a printed informed consent form after explanation of the treatment procedure and associated possible adverse effects of the proposed interventions such as discomfort, pain, anesthetic failure and systemic side effects at this stage. Randomization To ensure random selection, participants were allocated randomly into four groups with1:1 allocation ratio by using computer generated randomization (www.randome.org). The sequence was therefore generated. Allocation concealment mechanism: The sequentially generated numbers were placed in opaque envelopes until the intervention was conducted, and each participant was asked to select an envelope that determines which group of intervention was assumed. Implementation: Co-researcher used computer generated randomization for participants who achieve eligibility criteria and accordingly participants were enrolled in either of the groups under study. Blinding Both the participants, the operator who initiated endodontic treatment and monitored the pain, and the statistician were blinded to the anesthetic techniques used. Intervention Diagnosis was confirmed through history reporting spontaneous pain, a moderate to severe painful response that persists after thermal stimulation, a prolonged response to cold testing with Endo-Ice (1,1,1,2 tetrafluoroethane; Hygenic Corp, Akron, OH), absence of percussion sensitivity and the periapical aspect of the tooth in the bidimensional periapical radiograph was normal. Matching vital contralateral teeth were also tested to ensure an accurate diagnosis and to serve as controls. To prevent bias, this diagnostic step was performed by one investigator (AH), while another investigator (DK) was responsible for administration of all anesthetic injections (DK), and a third investigator (SS) was responsible for root canal treatment procedures and pain recording. All investigators have a minimum of 12 years of clinical experience in endodontics. One hundred and eighty-five patients consecutively visited were assessed for eligibility. Twenty-five patients were excluded for different reasons and the others (eighty-four female and seventy-six male patients) were allocated to the trial (Figure 1) and randomly assigned into 4 groups (n=40) as follows: Group 1 (IANB): After determining the injection site and aspiration, 3.6ml of the anesthetic solution was administered using the standard inferior alveolar nerve block (IANB), this was considered the control group. Group 2 (IANB + IO): A standard IANB was administered the same as for Group 1, followed by a supplemental intraosseous infusion (IO) injection using the Anesto system (W&H Dentalwerk Bürmoos, Austria). To ensure comfort during the procedure, 0.1ml of anesthetic solution was infiltrated at the perforation site using the standard syringe. The perforation site was selected near the junction of the attached and unattached gingival tissues, immediately distal to the first molar. Perforation was accomplished by operating the Anesto handpiece at full speed, with constant moderate pressure maintained until the perforator was felt to 'drop' into the cancellous bone. 1.8mL of the anesthetic solution was then deposited over a 60-second period. The Anesto handpiece was again retracted and, with the perforator rotating, removed from the injection site. Group 3 (IANB + PDL): A standard IANB was administered the same as for groups 1 and 3, followed by a supplemental periodontal ligament (PDL) injection. The needle was wedged with force into the PDL space between the tooth and the alveolar crest of the bone, at 30-degrees to the long axis of the tooth. The thumb and index fingers of the left hand supported the needle to prevent buckling. The handle of the syringe was squeezed firmly until backpressure was achieved. Then a total of 1.8ml of the anesthetic solution were injected mesially and distally to the treated molar. Group 4 (IANB + BI): A standard IANB was administered the same as for groups 1, 2 and 3, followed by a supplemental buccal infiltration at the buccal side of the affected tooth. A total of 1.8ml of the anesthetic solution were injected halfway the mesiodistal width of the clinical crown. IANB, PDL and BI injections were performed with a conventional dental syringe (indicate the brand) and a 27-G needle at a rate of 2 mL/min. The anesthetic solution used for all techniques was Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain). The efficacy of anesthesia was determined by the following: (1) confirmation of lip numbness, (2) negative response to Endo-Ice, (3) negative response to the maximum output of the electric pulp tester (Parkell, Edgewood, NY, USA). Root canal treatment procedure was later initiated, and the patients were asked to rate their pain using a visual analogue scale (VAS). Pain was scored as follows: Score 0, no pain; Score 1, mild pain; Score 2, moderate pain; or Score 3, severe pain. After rubber dam placement and during caries removal, access preparation and pulpectomy, success of the anesthetic technique was determined by VAS. The technique was considered as a 'success' when the patient reported no pain (VAS = 0 or 1) and as a 'failure' otherwise (VAS \>1). Heart rate changes were monitored with a finger pulse oximeter (Medlinket, Shenzhen Med-link Electronics, Shenzhen, China). It was recorded from 2 min before to 5 min after injection, at 30-s intervals. The mean heart rate for each injection was recorded. Statistical analysis All analyses were undertaken with IBM SPSS Statistics (SPSS 26.0; SPSS Inc., Chicago, IL). The anesthetic success rates were analyzed using the chi-square test. Age differences were analyzed using One Way ANOVA, gender differences were analyzed using the Fischer Exact test while heart rate changes were analysed with Kruskal Wallis test, being non-normally distributed. Statistically significant differences were set at the P \< 0.05 level

Interventions

PROCEDURElocal anesthesia

technique for local anesthesia

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Allocation concealment mechanism: The sequentially generated numbers were placed in opaque envelopes until the intervention was conducted, and each participant was asked to select an envelope that determines which group of intervention was assumed.

Intervention model description

This study was a prospective, randomized, parallel, triple blinded, clinical trial.

Eligibility

Sex/Gender
ALL
Age
21 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients included in the study were healthy males and females * (Category: American Society of Anesthesiologists class 1) * aged 21-49 years * with no physical disability, facial paresthesia or psychological problems * presenting with a single vital mature mandibular first molar, with signs and/or symptoms of symptomatic irreversible pulpitis

Exclusion criteria

* Pregnant women * patients who took analgesics or other medications that would alter the inflammatory response of the pulp or provide analgesia 6- hours pre-operatively * those with known sensitivity to the pharmaceuticals used in this trial. * those with pathological periodontal pockets

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS)15 minutes from delivery of anesthesiathe patients were asked to rate their pain using a Verbal rating scale (VRS). Pain was scored as follows: Score 0, no pain; Score 1, mild pain; Score 2, moderate pain; or Score 3, severe pain. After rubber dam placement and during caries removal, access preparation and pulpectomy, success of the anesthetic technique was determined by NRS. The technique was considered as a 'success' when the patient reported no pain (VRS = 0 or 1) and as a 'failure' otherwise (vRS \>1).

Secondary

MeasureTime frameDescription
Changes in the Heart Rate Before, During and After the Injectionassessed from 2 min before to 5 min after injection (at 30-s intervals)beat per minute measured by a finger pulse oximeter

Countries

Egypt

Participant flow

Participants by arm

ArmCount
IANB/Inferior Alveolar Nerve Block
patients were given a standard IANB with 3.6 ml Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain). local anesthesia: technique for local anesthesia
40
IANB+IO
patients were given a standard IANB (1.8 ml) followed by an intra-osseous supplemental injection (1.8 ml) Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain). local anesthesia: technique for local anesthesia
40
IANB+PDL
patients were given a standard IANB (1.8 ml) followed by a PDL supplemental injection (1.8 ml) with Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain). local anesthesia: technique for local anesthesia
40
IANB+BI
patients were given a standard IANB (1.8 ml) followed by a Buccal infiltration injection (1.8 ml) with Articaine HCL 4% with 1:100,000 adrenaline (Artinibsa, Inibsa, Barcelona, Spain). local anesthesia: technique for local anesthesia
40
Total160

Baseline characteristics

CharacteristicTotalIANB+IOIANB+PDLIANB+BIIANB/Inferior Alveolar Nerve Block
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
160 Participants40 Participants40 Participants40 Participants40 Participants
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
Egypt
160 participants40 participants40 participants40 participants40 participants
Sex: Female, Male
Female
102 Participants28 Participants26 Participants23 Participants25 Participants
Sex: Female, Male
Male
58 Participants12 Participants14 Participants17 Participants15 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 400 / 400 / 400 / 40
other
Total, other adverse events
0 / 400 / 400 / 400 / 40
serious
Total, serious adverse events
0 / 400 / 400 / 400 / 40

Outcome results

Primary

Number of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS)

the patients were asked to rate their pain using a Verbal rating scale (VRS). Pain was scored as follows: Score 0, no pain; Score 1, mild pain; Score 2, moderate pain; or Score 3, severe pain. After rubber dam placement and during caries removal, access preparation and pulpectomy, success of the anesthetic technique was determined by NRS. The technique was considered as a 'success' when the patient reported no pain (VRS = 0 or 1) and as a 'failure' otherwise (vRS \>1).

Time frame: 15 minutes from delivery of anesthesia

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
IANB/Inferior Alveolar Nerve BlockNumber of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS)16 Participants
IANB+IONumber of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS)37 Participants
IANB+PDLNumber of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS)29 Participants
IANB+BINumber of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS)26 Participants
Secondary

Changes in the Heart Rate Before, During and After the Injection

beat per minute measured by a finger pulse oximeter

Time frame: assessed from 2 min before to 5 min after injection (at 30-s intervals)

ArmMeasureGroupValue (MEAN)Dispersion
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection2 minutes72 beat per minutesStandard Deviation 4
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection1.5 minutes74 beat per minutesStandard Deviation 5
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection0 minutes75 beat per minutesStandard Deviation 6
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection-1.5 minutes71 beat per minutesStandard Deviation 4
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection1 minute74 beat per minutesStandard Deviation 5
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection0.5 minute76 beat per minutesStandard Deviation 4
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection-2 minutes72 beat per minutesStandard Deviation 4
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection4 minutes72 beat per minutesStandard Deviation 4
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection2.5 minutes72 beat per minutesStandard Deviation 4
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection-1 minute71 beat per minutesStandard Deviation 5
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection5 minutes71 beat per minutesStandard Deviation 3
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection3.5 minutes72 beat per minutesStandard Deviation 3
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection3 minutes71 beat per minutesStandard Deviation 3
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection-0.5 minute72 beat per minutesStandard Deviation 5
IANB/Inferior Alveolar Nerve BlockChanges in the Heart Rate Before, During and After the Injection4.5 minutes71 beat per minutesStandard Deviation 4
IANB+IOChanges in the Heart Rate Before, During and After the Injection3.5 minutes72 beat per minutesStandard Deviation 4
IANB+IOChanges in the Heart Rate Before, During and After the Injection-2 minutes72 beat per minutesStandard Deviation 5
IANB+IOChanges in the Heart Rate Before, During and After the Injection-1.5 minutes72 beat per minutesStandard Deviation 5
IANB+IOChanges in the Heart Rate Before, During and After the Injection-1 minute71 beat per minutesStandard Deviation 4
IANB+IOChanges in the Heart Rate Before, During and After the Injection-0.5 minute72 beat per minutesStandard Deviation 5
IANB+IOChanges in the Heart Rate Before, During and After the Injection0 minutes80 beat per minutesStandard Deviation 7
IANB+IOChanges in the Heart Rate Before, During and After the Injection0.5 minute85 beat per minutesStandard Deviation 5
IANB+IOChanges in the Heart Rate Before, During and After the Injection1 minute84 beat per minutesStandard Deviation 6
IANB+IOChanges in the Heart Rate Before, During and After the Injection1.5 minutes83 beat per minutesStandard Deviation 7
IANB+IOChanges in the Heart Rate Before, During and After the Injection2 minutes80 beat per minutesStandard Deviation 6
IANB+IOChanges in the Heart Rate Before, During and After the Injection2.5 minutes77 beat per minutesStandard Deviation 5
IANB+IOChanges in the Heart Rate Before, During and After the Injection3 minutes74 beat per minutesStandard Deviation 4
IANB+IOChanges in the Heart Rate Before, During and After the Injection4 minutes71 beat per minutesStandard Deviation 3
IANB+IOChanges in the Heart Rate Before, During and After the Injection4.5 minutes72 beat per minutesStandard Deviation 3
IANB+IOChanges in the Heart Rate Before, During and After the Injection5 minutes71 beat per minutesStandard Deviation 2
IANB+PDLChanges in the Heart Rate Before, During and After the Injection-0.5 minute72 beat per minutesStandard Deviation 4
IANB+PDLChanges in the Heart Rate Before, During and After the Injection3.5 minutes72 beat per minutesStandard Deviation 4
IANB+PDLChanges in the Heart Rate Before, During and After the Injection2.5 minutes72 beat per minutesStandard Deviation 3
IANB+PDLChanges in the Heart Rate Before, During and After the Injection-1.5 minutes70 beat per minutesStandard Deviation 4
IANB+PDLChanges in the Heart Rate Before, During and After the Injection4.5 minutes71 beat per minutesStandard Deviation 3
IANB+PDLChanges in the Heart Rate Before, During and After the Injection4 minutes71 beat per minutesStandard Deviation 3
IANB+PDLChanges in the Heart Rate Before, During and After the Injection2 minutes72 beat per minutesStandard Deviation 5
IANB+PDLChanges in the Heart Rate Before, During and After the Injection-2 minutes71 beat per minutesStandard Deviation 4
IANB+PDLChanges in the Heart Rate Before, During and After the Injection0.5 minute75 beat per minutesStandard Deviation 6
IANB+PDLChanges in the Heart Rate Before, During and After the Injection3 minutes72 beat per minutesStandard Deviation 4
IANB+PDLChanges in the Heart Rate Before, During and After the Injection0 minutes74 beat per minutesStandard Deviation 5
IANB+PDLChanges in the Heart Rate Before, During and After the Injection1.5 minutes73 beat per minutesStandard Deviation 5
IANB+PDLChanges in the Heart Rate Before, During and After the Injection1 minute73 beat per minutesStandard Deviation 4
IANB+PDLChanges in the Heart Rate Before, During and After the Injection-1 minute71 beat per minutesStandard Deviation 5
IANB+PDLChanges in the Heart Rate Before, During and After the Injection5 minutes71 beat per minutesStandard Deviation 1
IANB+BIChanges in the Heart Rate Before, During and After the Injection-0.5 minute71 beat per minutesStandard Deviation 3
IANB+BIChanges in the Heart Rate Before, During and After the Injection1.5 minutes71 beat per minutesStandard Deviation 4
IANB+BIChanges in the Heart Rate Before, During and After the Injection2 minutes71 beat per minutesStandard Deviation 4
IANB+BIChanges in the Heart Rate Before, During and After the Injection4.5 minutes71 beat per minutesStandard Deviation 2
IANB+BIChanges in the Heart Rate Before, During and After the Injection2.5 minutes70 beat per minutesStandard Deviation 4
IANB+BIChanges in the Heart Rate Before, During and After the Injection-1 minute70 beat per minutesStandard Deviation 4
IANB+BIChanges in the Heart Rate Before, During and After the Injection3 minutes71 beat per minutesStandard Deviation 2
IANB+BIChanges in the Heart Rate Before, During and After the Injection-1.5 minutes69 beat per minutesStandard Deviation 4
IANB+BIChanges in the Heart Rate Before, During and After the Injection3.5 minutes71 beat per minutesStandard Deviation 3
IANB+BIChanges in the Heart Rate Before, During and After the Injection5 minutes72 beat per minutesStandard Deviation 3
IANB+BIChanges in the Heart Rate Before, During and After the Injection0 minutes72 beat per minutesStandard Deviation 5
IANB+BIChanges in the Heart Rate Before, During and After the Injection4 minutes72 beat per minutesStandard Deviation 3
IANB+BIChanges in the Heart Rate Before, During and After the Injection0.5 minute72 beat per minutesStandard Deviation 4
IANB+BIChanges in the Heart Rate Before, During and After the Injection-2 minutes71 beat per minutesStandard Deviation 5
IANB+BIChanges in the Heart Rate Before, During and After the Injection1 minute71 beat per minutesStandard Deviation 4

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026